Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$18.86 USD
+0.37 (2.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.84 -0.02 (-0.11%) 7:18 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.86 USD
+0.37 (2.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.84 -0.02 (-0.11%) 7:18 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Zacks News
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.70% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
by Zacks Equity Research
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
by Zacks Equity Research
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 87.50% and 2.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 119.44% and 11.02%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
by Zacks Equity Research
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 3.77% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Smart for Life, Inc. (SMFL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Smart for Life, Inc. (SMFL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
by Zacks Equity Research
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -35.71% and 0.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -250% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Forget Bargains, Play 5 Stocks With Rising P/E Instead
by Sanghamitra Saha
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.